AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca bets on continued oncology demand for 2026 growth
Publish Date: 2026-02-10 11:06:00
Source Domain: www.pharmaceutical-technology.com
AstraZeneca reported full year 2025 revenue of $58.7bn, up 8% at CER compared to 2024. Image credit: Michael Vi via Shutterstock.com.
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical pressures and patent expiry headwinds.
AstraZeneca reported full year 2025 revenue of $58.7bn, up 8% at constant exchange rate (CER) compared to 2024. Oncology drug sales were a big driver for the drugmaker’s growth, with revenue in the business increasing 14% to $25.6bn in 2025 compared to the year before.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
Lung cancer drug Tagrisso (osimertinib) was the top-selling product in the oncology segment, generating $7.25bn in sales for the year. Immunotherapy Imfinzi netted $6.06bn in 2025, boosted by US approvals in bladder cancer and gastric and gastroesophageal junction (GEJ) cancers. Sales for HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) saw a significant sales increase, surging 40% to reach $2.78bn in 2025.
In an earnings call, Imfinzi and Enhertu were earmarked by AstraZeneca’s senior leadership team as key revenue drivers for 2026, boosted by recent and upcoming cancer indication expansions.
Enhertu, co-marketed with Daiichi Sankyo, is forecast to generate global sales of $14.3bn in 2031, according to analysis by…
